Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Trends in Cancer Models 2020

Trends in Cancer Models 2020 Agenda

Print Agenda

Thursday, 8 October 2020


Conference Registration, Materials Pick-Up, Morning Coffee and Pastries


Mindy GoldsboroughKeynote Presentation

Welcome and Introduction
Mindy Goldsborough, Chief Scientific Officer, ATCC, United States of America


James ClintonKeynote Presentation

Next-Generation Cancer Models from the Human Cancer Models Initiative
James Clinton, Senior Scientist, American Type Culture Collection (ATCC), United States of America

ATCC is actively pursuing the development of improved in vitro models as part of its mission to support the scientific community. This desire to support innovative in vitro model development led to ATCC’s involvement in the Human Cancer Models Initiative (HCMI), an international collaborative effort to generate 1000 new human cancer models. This initiative was born out of a recognition that that currently available preclinical cancer models are often inadequate for the study of cancer biology, drug discovery, personalized therapeutics, and biomarker identification. This can be attributed to an insufficient diversity of available models, as well as the realization that existing models often lack biological and genetic relevance to tumors in vivo. To address these deficiencies, advanced culture methods, including three-dimensional organoids, are being utilized to generate novel primary tissue-derived models from human cancers that are underrepresented by existing cell lines. Here we provide an overview of the HCMI, and of the technologies driving the development of these “next-generation” models that hold promise to transform in vitro cancer research.


Pancreatic Cancer Patient-Derived Organoids as a Tool for Personalized Medicine
Hervé Tiriac, Assistant Research Scientist, University of California-San Diego, United States of America

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we find that PDO therapeutic profiles paralleled patient outcomes and that PDOs enable longitudinal assessment of chemo-sensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemo-sensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemo-refractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.


Morning Networking Break


Generation and Use of Patient-Derived Organoids in Translational Research
Dennis Plenker, Research Investigator, Cold Spring Harbor Laboratory, United States of America


Networking Lunch


M. Laura MartinKeynote Presentation

Next Generation Cancer Models in Precision Medicine
M. Laura Martin, Director of ex vivo Models, Englander Institute for Precision Medicine, Weill Cornell Medicine, United States of America

Precision medicine aims to match individual patients with the best treatment based on the patients’ tumors biologic and molecular characteristics. As part of the Englander Institute for Precision Medicine at Weill Cornell Medical College, the Tumor Organoid Platform is an active program focused on the development of Next Generation Cancer Models (NGCMs) derived from metastatic and primary anatomic sites obtained through biopsies, surgical resections and rapid autopsy procedures. In this setting, we are able to extend our personalized medicine program to include high throughput drug screening, which can be validated through genomic sequencing and both in vivo and in vitro models. To date we have established more than a 100 NGCMs, spanning a range of 11 primary tumor types (colorectal, breast, lung, stomach, esophagus, ovary, endometrium, pancreas, kidney, bladder and prostate) that can be used for a variety of experiments. A new NGCM is successfully established when it has been expanded up to passage 5 and has been able to be biobanked. At P5, they are subjected to tumor verification assays such as Whole Exome Sequencing, RNA sequencing and immunohistochemistry. Our recently acquired high throughput drug screening (HTDS) platform is an integrative robotic system with capabilities such as high content imaging and endpoint reads. We are currently validating image-based cell viability measurements using our NGCMs compared with the traditionally used endpoint measurement of ATP luminescence.


Senior Scientific Manager, Functional Genomics, Genentech


Afternoon Coffee Break


Adaptive Biotech Presentation

Panel Discussion


Panel Discussion Moderated by Dr. Mindy Goldsborough, CSO, ATCC


Posters and Networking Reception


Close of Summit

Add to Calendar ▼2020-10-08 00:00:002020-10-08 00:00:00Europe/LondonTrends in Cancer Models 2020Trends in Cancer Models 2020 in San Francisco, CaliforniaSan Francisco,